Trastuzumab Deruxtecan
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Trastuzumab Deruxtecan
- Trastuzumab deruxtecan: From Its Registered Oncology Use to Drug-Induced Osteoporosis
Trastuzumab deruxtecan: From Its Registered Oncology Use to Drug-Induced Osteoporosis
One-Sentence Summary
Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate (a topoisomerase I inhibitor payload attached to an antibody) used in oncology, and it is registered in Singapore as ENHERTU. The TxGNN model ranks drug-induced osteoporosis as its top predicted new indication, but there are 0 clinical trials and 0 publications supporting this direction. This is a model-only prediction (Evidence Level L5) with no identifiable mechanistic link, so the recommendation is to hold.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (the approved indication text in the Singapore licence record is empty) |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate with a topoisomerase I inhibitor payload, designed to deliver cytotoxic therapy to HER2-expressing tumours.
On review, the prediction is not mechanistically reasonable. HER2-targeted cytotoxic delivery has no known connection to bone metabolism or osteoporosis. The high TxGNN score is a graph-based computational result, with no clinical or literature support behind it.
The other top-ranked predictions share the same weakness. They include severe nonproliferative diabetic retinopathy, diabetic retinopathy, bronchitis, diabetic cataract and several tumour or lesion types without HER2 dependence. For bronchitis in particular, the drug carries a boxed warning for interstitial lung disease/pneumonitis, so respiratory risk argues against use.
Clinical Trial Evidence
Currently no related clinical trials registered for drug-induced osteoporosis.
Literature Evidence
Currently no related literature available for drug-induced osteoporosis.
For reference, the literature retrieved for the rank-8 prediction ("ductal or ductular proliferation") consists mainly of HER2-positive and HER2-low breast, pancreatic and salivary ductal cancer reports. These are not evidence for the top-ranked indication, and several are adverse-event case reports (Fanconi syndrome, dermatomyositis, interstitial lung disease). They concern existing oncology use rather than repurposing, and should be evaluated separately.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16352P | ENHERTU Powder for Concentrate for Solution for Infusion 100mg/vial (Baxter Oncology GmbH) | Infusion, solution concentrate | Not stated in the licence record |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Antibody-drug conjugate with a cytotoxic topoisomerase I inhibitor payload (targeted therapy delivering a cytotoxic agent) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions (at minimum CBC, liver and renal function; respiratory monitoring for interstitial lung disease/pneumonitis) |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Safety Considerations
- Key Warnings: The compiled data contain no label text. The drug carries a boxed warning for interstitial lung disease/pneumonitis, and case reports describe Fanconi syndrome, dermatomyositis and interstitial lung disease after treatment.
- Drug Interactions: 42 interactions were identified. Those listed at Major level include deferiprone, samarium (153Sm) lexidronam, adalimumab, baricitinib, certolizumab pegol, cladribine, leflunomide and natalizumab. Moderate-level examples include palifermin, strontium chloride Sr-89, roflumilast, chloramphenicol, alefacept, alemtuzumab, anakinra, azathioprine, canakinumab, dimethyl fumarate and niraparib. Many of these are immunosuppressive or myelosuppressive agents. Only 20 of the 42 are listed here.
For the full set of warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a graph-based score, with no trials, no literature and no plausible mechanism linking a HER2-directed cytotoxic conjugate to osteoporosis. Using a toxic oncology agent in a non-oncologic bone condition would also raise a clear risk-benefit concern.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA (currently a blocking data gap that prevents safety screening)
- Mechanism of action data from DrugBank
- The approved indication text for the Singapore licence
- Any preclinical or mechanistic evidence linking the drug to bone metabolism, which does not currently exist
- A risk-benefit justification for cytotoxic therapy in a non-oncologic indication
- Evaluation of the approved HER2 oncology uses separately from this repurposing question
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.